AR065348A1 - Composicion farmaceutica que comprende un agonista no peptidico del receptor de tpo, combinacion farmaceutica con un agente anti-neoplasico y sus usos para preparar un medicamento tratamiento del cancer - Google Patents
Composicion farmaceutica que comprende un agonista no peptidico del receptor de tpo, combinacion farmaceutica con un agente anti-neoplasico y sus usos para preparar un medicamento tratamiento del cancerInfo
- Publication number
- AR065348A1 AR065348A1 ARP080100631A ARP080100631A AR065348A1 AR 065348 A1 AR065348 A1 AR 065348A1 AR P080100631 A ARP080100631 A AR P080100631A AR P080100631 A ARP080100631 A AR P080100631A AR 065348 A1 AR065348 A1 AR 065348A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- aryl
- cycloalkyl
- alkyl
- hydrogen
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 230000000118 anti-neoplastic effect Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 14
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 6
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 6
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000003107 substituted aryl group Chemical group 0.000 abstract 4
- -1 -S (O) nR4 Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 abstract 2
- 125000004423 acyloxy group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 229940034982 antineoplastic agent Drugs 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 abstract 1
- 229960004562 carboplatin Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89023607P | 2007-02-16 | 2007-02-16 | |
| US89255207P | 2007-03-02 | 2007-03-02 | |
| US90820507P | 2007-03-27 | 2007-03-27 | |
| US94934707P | 2007-07-12 | 2007-07-12 | |
| US95228907P | 2007-07-27 | 2007-07-27 | |
| US96919207P | 2007-08-31 | 2007-08-31 | |
| US97721607P | 2007-10-03 | 2007-10-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065348A1 true AR065348A1 (es) | 2009-06-03 |
Family
ID=39690807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080100631A AR065348A1 (es) | 2007-02-16 | 2008-02-14 | Composicion farmaceutica que comprende un agonista no peptidico del receptor de tpo, combinacion farmaceutica con un agente anti-neoplasico y sus usos para preparar un medicamento tratamiento del cancer |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20100075928A1 (OSRAM) |
| EP (1) | EP2124547B3 (OSRAM) |
| JP (1) | JP5511391B2 (OSRAM) |
| KR (1) | KR101447763B1 (OSRAM) |
| CN (1) | CN101662937B (OSRAM) |
| AR (1) | AR065348A1 (OSRAM) |
| AU (1) | AU2008216106C1 (OSRAM) |
| BR (1) | BRPI0807940B8 (OSRAM) |
| CA (1) | CA2678358C (OSRAM) |
| CR (1) | CR10997A (OSRAM) |
| DK (1) | DK2124547T6 (OSRAM) |
| EA (1) | EA017715B1 (OSRAM) |
| ES (1) | ES2675070T7 (OSRAM) |
| FI (1) | FI2124547T4 (OSRAM) |
| HU (1) | HUE038563T2 (OSRAM) |
| IL (2) | IL200319A (OSRAM) |
| MA (1) | MA31202B1 (OSRAM) |
| MX (1) | MX2009008822A (OSRAM) |
| NZ (1) | NZ579068A (OSRAM) |
| PE (1) | PE20081784A1 (OSRAM) |
| PL (1) | PL2124547T5 (OSRAM) |
| PT (1) | PT2124547T (OSRAM) |
| SI (1) | SI2124547T2 (OSRAM) |
| TR (1) | TR201809010T4 (OSRAM) |
| TW (1) | TW200906393A (OSRAM) |
| UY (1) | UY30915A1 (OSRAM) |
| WO (1) | WO2008101141A2 (OSRAM) |
| ZA (1) | ZA200905532B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110160130A1 (en) * | 2007-02-16 | 2011-06-30 | Connie Erickson-Miller | Cancer treatment method |
| US20110129550A1 (en) * | 2007-02-16 | 2011-06-02 | Connie Erickson-Miller | Cancer treatment method |
| ECSP077628A (es) | 2007-05-03 | 2008-12-30 | Smithkline Beechman Corp | Nueva composición farmacéutica |
| EA022915B1 (ru) * | 2007-10-09 | 2016-03-31 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Способы лечения острого миелоидного лейкоза и миелодиспластического синдрома |
| JP2012528184A (ja) | 2009-05-29 | 2012-11-12 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | トロンボポエチンアゴニスト化合物の投与の方法 |
| CN103079551A (zh) * | 2010-09-01 | 2013-05-01 | 诺华有限公司 | Hdac抑制剂与血小板减少症药物的组合 |
| US9962370B2 (en) | 2013-03-15 | 2018-05-08 | Ligand Pharmaceuticals Incorporated | Methods of treatment associated with the granulocyte colony-stimulating factor receptor |
| IL262746B (en) * | 2016-05-06 | 2022-09-01 | Taris Biomedical Llc | A method for treating urothelial cancer in the lower system |
| RU2675695C1 (ru) * | 2018-03-06 | 2018-12-24 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации | Способ лечения рака предстательной железы высокого и очень высокого риска |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5559235A (en) * | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
| US5342947A (en) | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| AP9300587A0 (en) * | 1992-11-12 | 1995-05-05 | Glaxo Inc | Water soluble camptothecin derivatives. |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| US5491237A (en) * | 1994-05-03 | 1996-02-13 | Glaxo Wellcome Inc. | Intermediates in pharmaceutical camptothecin preparation |
| US6316652B1 (en) * | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| WO1999011262A1 (en) | 1997-09-02 | 1999-03-11 | Roche Diagnostics Gmbh | Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia |
| WO2001007423A1 (en) | 1999-07-26 | 2001-02-01 | Shionogi & Co., Ltd. | Drug compositions exhibiting thrombopoietin agonism |
| EP1104674A1 (de) | 1999-11-10 | 2001-06-06 | Curacyte AG | O,o'-Dihydroxyazofarbstoffe als Bestandteile von Arzneimitteln mit TPO-Agonistischer oder -Synergetischer Wirkung |
| CA2390095C (en) * | 1999-11-10 | 2013-01-08 | M. Rigdon Lentz | Method and system to remove cytokine inhibitor in patients |
| TWI284639B (en) * | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| CY2010012I2 (el) | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
| AU2001260661A1 (en) * | 2000-05-30 | 2001-12-11 | Chugai Seiyaku Kabushiki Kaisha | Compounds exhibiting thrombopoietin-like activities |
| EP1284997B1 (en) * | 2000-05-31 | 2005-04-06 | Genzyme Corporation | Therapeutic compounds for ovarian cancer |
| ATE290882T1 (de) * | 2001-01-16 | 2005-04-15 | Glaxo Group Ltd | Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält |
| EP1361220A4 (en) | 2001-01-26 | 2005-09-07 | Shionogi & Co | CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM |
| JP4145655B2 (ja) | 2001-01-26 | 2008-09-03 | 塩野義製薬株式会社 | トロンボポエチン受容体アゴニスト作用を有するハロゲン化合物 |
| WO2002062775A1 (en) | 2001-02-02 | 2002-08-15 | Yamanouchi Pharmaceutical Co., Ltd. | 2-acylaminothiazole derivative or its salt |
| US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| EA007481B1 (ru) * | 2001-09-24 | 2006-10-27 | Тоск, Инк. | Цисплатиновые составы пониженной токсичности и способы их применения |
| EP2314586B1 (en) * | 2002-01-18 | 2016-09-14 | Astellas Pharma Inc. | 2-Acylaminothiazole derivative or salt thereof |
| TWI280128B (en) * | 2002-05-22 | 2007-05-01 | Smithkline Beecham Corp | 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| WO2004029049A1 (ja) * | 2002-09-30 | 2004-04-08 | Yamanouchi Pharmaceutical Co., Ltd. | 2-アシルアミノチアゾール誘導体の新規な塩 |
| WO2004096154A2 (en) | 2003-04-29 | 2004-11-11 | Smithkline Beecham Corporation | Methods for treating degenerative diseases/injuries |
| WO2005118551A2 (en) | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
| ATE486859T1 (de) | 2004-10-25 | 2010-11-15 | Ligand Pharm Inc | Verbindungen modulierende thrombopoietinaktivität und verfahren |
| AU2006318527A1 (en) | 2005-11-23 | 2007-05-31 | Ligand Pharmaceuticals Incorporated | Thrombopoietin activity modulating compounds and methods |
| BRPI0709286A2 (pt) | 2006-03-15 | 2011-07-05 | Ligand Pharm Inc | processo de sìntese de compostos para modulção da atividade da trombopoietina |
-
2008
- 2008-02-13 UY UY30915A patent/UY30915A1/es unknown
- 2008-02-14 TW TW097105201A patent/TW200906393A/zh unknown
- 2008-02-14 AR ARP080100631A patent/AR065348A1/es not_active Application Discontinuation
- 2008-02-14 PE PE2008000322A patent/PE20081784A1/es not_active Application Discontinuation
- 2008-02-15 NZ NZ579068A patent/NZ579068A/en not_active IP Right Cessation
- 2008-02-15 TR TR2018/09010T patent/TR201809010T4/tr unknown
- 2008-02-15 SI SI200831968T patent/SI2124547T2/sl unknown
- 2008-02-15 CA CA2678358A patent/CA2678358C/en active Active
- 2008-02-15 EA EA200970776A patent/EA017715B1/ru not_active IP Right Cessation
- 2008-02-15 JP JP2009550145A patent/JP5511391B2/ja active Active
- 2008-02-15 US US12/527,220 patent/US20100075928A1/en not_active Abandoned
- 2008-02-15 PL PL08729939.2T patent/PL2124547T5/pl unknown
- 2008-02-15 HU HUE08729939A patent/HUE038563T2/hu unknown
- 2008-02-15 DK DK08729939.2T patent/DK2124547T6/da active
- 2008-02-15 BR BRPI0807940A patent/BRPI0807940B8/pt active IP Right Grant
- 2008-02-15 KR KR1020097019224A patent/KR101447763B1/ko active Active
- 2008-02-15 WO PCT/US2008/054046 patent/WO2008101141A2/en not_active Ceased
- 2008-02-15 FI FIEP08729939.2T patent/FI2124547T4/fi active
- 2008-02-15 CN CN200880012425.7A patent/CN101662937B/zh active Active
- 2008-02-15 AU AU2008216106A patent/AU2008216106C1/en active Active
- 2008-02-15 MX MX2009008822A patent/MX2009008822A/es active IP Right Grant
- 2008-02-15 ES ES08729939T patent/ES2675070T7/es active Active
- 2008-02-15 PT PT87299392T patent/PT2124547T/pt unknown
- 2008-02-15 EP EP08729939.2A patent/EP2124547B3/en active Active
- 2008-07-02 US US12/166,686 patent/US20090022814A1/en not_active Abandoned
-
2009
- 2009-08-07 ZA ZA200905532A patent/ZA200905532B/xx unknown
- 2009-08-10 IL IL200319A patent/IL200319A/en active IP Right Grant
- 2009-08-26 CR CR10997A patent/CR10997A/es not_active Application Discontinuation
- 2009-08-31 MA MA32188A patent/MA31202B1/fr unknown
-
2015
- 2015-04-20 IL IL238394A patent/IL238394B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065348A1 (es) | Composicion farmaceutica que comprende un agonista no peptidico del receptor de tpo, combinacion farmaceutica con un agente anti-neoplasico y sus usos para preparar un medicamento tratamiento del cancer | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| AR030696A1 (es) | Derivados de hidroxi-1-azobenceno, composiciones farmaceuticas que los comprenden, uso de dichos compuestos en la fabricacion de medicamentos, proceso para preparar dichas composiciones, proceso para preparar dichos compuestos, metodo in vitro o ex vivo para aumentar la estimulacion de la maduracion | |
| CO2023003282A2 (es) | Nuevos derivados de psilocina que tienen propiedades de profármaco | |
| PA8785401A1 (es) | Derivados de bencimidazol | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| TN2009000180A1 (en) | NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF | |
| PE20201165A1 (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| CL2008001669A1 (es) | Compuestos derivados de piperidina/piperazina inhibidora de dgat-1; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento de la obesidad, dislipidemia, fibrosis hepatica y diabetes tipo ii, entre otras. | |
| CL2004000917A1 (es) | Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| AR071055A1 (es) | Compuestos espiro, composiciones farmaceuticas y medicamentos que los comprenden, agente promotor de la secrecion de insulina y usos para la preparacion de medicamentos y composiciones farmaceuticas | |
| MX420195B (es) | Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos | |
| CY1116183T1 (el) | Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης | |
| AR062737A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamento | |
| MX384744B (es) | Derivado de morfinano. | |
| MX391096B (es) | Formulación liposomal. | |
| AR046170A1 (es) | Derivados de pirimidin-2-amina y su uso como antagonistas del receptor de adenosina a 2b | |
| RU2013136895A (ru) | Новое бициклическое соединение или его соль | |
| RU2009114731A (ru) | Производное пиразолопиримидина | |
| UY29234A1 (es) | Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones. | |
| AR111176A1 (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos | |
| AR069306A1 (es) | Derivados de metil- bencimidazol como moduladores de receptor x de farnesoide(fxr) | |
| AR075348A1 (es) | Metodos y composiciones para tratar cancer de mama |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |